Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 3 results for icotrokinra, a new investigational treatment ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

In type 1 diabetes, the body’s own immune system turns against the pancreas. Cells meant to protect you start destroying ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Researchers reviewed a host of studies investigating diet plans in an effort to guide evidence-based recommendations for ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the ...

Research has yet to confirm a link between diet and psoriasis. But some psoriasis patients find that eliminating certain ...

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

A study co-led by Indiana University School of Medicine researchers presents a potential new strategy to prevent or slow the ...

A study co-led by Indiana University School of Medicine researchers presents a potential new strategy to prevent or slow the ...

The impact of psoriasis on quality of life goes beyond clinical measures, such as psoriasis area severity index (PASI) and ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...